{"nctId":"NCT01389323","briefTitle":"BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C","startDateStruct":{"date":"2011-09"},"conditions":["Hepatitis C"],"count":448,"armGroups":[{"label":"Arm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin","type":"EXPERIMENTAL","interventionNames":["Drug: Daclatasvir","Drug: Peg-Interferon Alfa-2a","Drug: Ribavirin"]}],"interventions":[{"name":"Daclatasvir","otherNames":["BMS-790052"]},{"name":"Peg-Interferon Alfa-2a","otherNames":["Pegasys"]},{"name":"Ribavirin","otherNames":["Copegus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants chronically infected with Hepatitis C virus (HCV) genotype 1\n* HCV RNA viral load of ≥10,000 IU/mL at screening\n* No previous exposure to interferon formulation, ribavirin or HCV direct antiviral agent\n* Self-described as Black-African American, Latino or White-Caucasian\n* Results of a liver biopsy obtained ≤36 months prior to first treatment compensated cirrhotics with HCV liver biopsy from any time prior to first treatment.\n\nCompensated cirrhotics were capped at approximately 25%\n\nExclusion Criteria:\n\n* Evidence of decompensated liver disease\n* Documented or suspected Hepatocellular carcinoma (HCC)\n* Positive for Hepatitis B or HIV 1/HIV 2 antibody at screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12)","description":"SVR12 was defined as Hepatitis C Virus (HCV) RNA levels \\<lower limit of quantitation (LLOQ), (target detected or target not detected) at Post-treatment Week 12. The limit of detection for HCV RNA was 10 IU/mL and the LLOQ was 25 IU/mL. For analysis purpose, participants were assigned to following 3 race/ethnicity cohorts: Black/African American, Latino, and White non-Latino. Some participants were represented in more than one race/ethnicity cohort.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null},{"groupId":"OG001","value":"57.0","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12) With rs12979860 Single Nucleotide Polymorphisms at Baseline in the Interleukin-28B Gene","description":"SVR12 was defined as Hepatitis C Virus (HCV) RNA levels \\<lower limit of quantitation (LLOQ), (target detected or target not detected) at Post-treatment Week 12. The limit of detection for HCV RNA was 10 IU/mL and the LLOQ was 25 IU/mL. For analysis purpose, participants were assigned to following 3 race/ethnicity cohorts: Black/African American, Latino, and White non-Latino. Some participants were represented in more than one race/ethnicity cohort.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"70.8","spread":null},{"groupId":"OG002","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null},{"groupId":"OG001","value":"50.7","spread":null},{"groupId":"OG002","value":"58.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":null},{"groupId":"OG001","value":"64.3","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels <Lower Limit of Quantitation (LLOQ), Target Detected or Target Not Detected, at Specified Time Points","description":"The limit of detection for HCV RNA levels was 10 IU/mL and the LLOQ was 25 IU/mL. Data for post-treatment Weeks 36 and 48 were based on participants who had achieved virologic response (defined as HCV RNA levels \\<LLOQ, target not detected) at both Weeks 4 and 12, and completed 24 weeks of study treatment. For analysis purpose, participants were assigned to following 3 race/ethnicity cohorts: Black/African American, Latino, and White non-Latino. Some participants were represented in more than one race/ethnicity cohort.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":null},{"groupId":"OG001","value":"44.9","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":null},{"groupId":"OG001","value":"72.0","spread":null},{"groupId":"OG002","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null},{"groupId":"OG001","value":"85.0","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"81.3","spread":null},{"groupId":"OG002","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"81.3","spread":null},{"groupId":"OG002","value":"76.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"80.4","spread":null},{"groupId":"OG002","value":"76.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.0","spread":null},{"groupId":"OG001","value":"77.6","spread":null},{"groupId":"OG002","value":"56.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.4","spread":null},{"groupId":"OG001","value":"79.4","spread":null},{"groupId":"OG002","value":"93.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"57.0","spread":null},{"groupId":"OG002","value":"63.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels <Lower Limit of Quantitation (LLOQ), Target Not Detected, at Specified Time Points","description":"The limit of detection for HCV RNA levels was 10 IU/mL and the LLOQ was 25 IU/mL. For analysis purpose, participants were assigned to following 3 race/ethnicity cohorts: Black/African American, Latino, and White non-Latino. Some participants were represented in more than one race/ethnicity cohort.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"12.1","spread":null},{"groupId":"OG002","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":null},{"groupId":"OG001","value":"27.1","spread":null},{"groupId":"OG002","value":"30.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":null},{"groupId":"OG001","value":"68.2","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null},{"groupId":"OG001","value":"75.7","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null},{"groupId":"OG001","value":"73.8","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":null},{"groupId":"OG001","value":"74.8","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"58.9","spread":null},{"groupId":"OG002","value":"43.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"78.5","spread":null},{"groupId":"OG002","value":"93.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null},{"groupId":"OG001","value":"55.1","spread":null},{"groupId":"OG002","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"55.1","spread":null},{"groupId":"OG002","value":"63.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Treatment-related AEs, and Who Died","description":"An AE was defined as any new unfavorable symptom, sign, or disease or worsening of a pre-existing condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Treatment-related AE was defined as an AE that had certain, probable, possible, or unknown relationship to study drug. For analysis purpose, participants were assigned to following 4 race/ethnicity cohorts: Black/African American, White/Caucasian, Latino and Non-Latino. Some participants were represented in more than one race/ethnicity cohort.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"16","spread":null},{"groupId":"OG004","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"18","spread":null},{"groupId":"OG004","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"126","spread":null},{"groupId":"OG004","value":"219","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":246},"commonTop":["Fatigue","Headache","Anaemia","Nausea","Rash"]}}}